Previous 10 | Next 10 |
VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period. By upregulation of immunomodulatory, Ainos' VELDONA® formulation demonstrates efficacy against new variant virus ...
Ainos ( NASDAQ: AIMD ) filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation Veldona to treat mild symptoms related to COVID-19. Earlier in August, the co...
SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announ...
Ainos ( NASDAQ: AIMD ) signed an agreement under which Swiss Pharmaceutical (Taiwan) will test, manufacture and package the company's Veldona product candidates for use in planned clinical trials. Ainos said it plans to submit an investigational new drug application to...
SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announ...
Amarillo Biosciences press release ( NASDAQ: AIMD ): Q2 GAAP EPS of -$0.01. Revenue of $636.62M (+213.6% Y/Y). For further details see: Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M
SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announ...
SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announ...
COVID-19 therapy and test developer Ainos ( NASDAQ: AIMD ) saw its stock sink 17% Wednesday, the day after it uplisted its shares to Nasdaq and conducted a $3M initial public offering. Shares of the medtech group opened at $3.56, later sliding to hit a low of $2.90 in mornin...
COVID-19 test and therapy developer Ainos ( OTCPK:AIMD ) conducted a reverse stock split, uplisted its stock to Nasdaq and held a downsized $3M initial public offering on Tuesday. Ainos offered 780K units at $4.25 per unit, raising around $3.3M. Each unit consisted of one sh...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen product targeting at-home testing Next-Gen Ainos Flora will advance with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...